Adicet Bio Shares Halted Ahead of Data Readout That May Steer ACET
Adicet Bio shares didn’t move Monday with U.S. markets shut for Memorial Day. Investors are watching the stock after it jumped late last week. Shares ended Friday at $8.30, up 5.2% on the day and gaining 10.7% over the period from May 18 to 22, ahead of key clinical data. Adicet’s next update is coming up sooner than before. The company says it expects to have Phase 1 data for prulacabtagene leucel, or prula-cel, in at least 20 lupus nephritis and systemic lupus erythematosus patients, with at least six months of follow-up, by mid-2026.)